RE: Onehanded on lse15 Jun 2020 10:40
GB, many thanks for your reply.
From the placing RNS on 6th Dec 2019 it stated...
"The Company guided revenues of £1 million in 2019 and four times that for 2020 to £4 million. Even with cash in the bank, a very low-geared (8 per cent.) balance sheet and profitability in sight, it is necessary for the Company to provide verifiable assurances during a client's due diligence process that its cash buffer is strong throughout the duration of each client's engagement with the Company. The monies raised will provide this buffer and enable this continued rapid growth of sales to many leading global skincare companies through the expansion of both facilities and employees. With the visibility we have of sales into next year, 2020 is already looking to be a good year for Integumen."
Further down in the RNS it stated cash in bank of £477k as of 30/9/19.
At 31/12/19 results show that cash in bank was £1.2m despite a £1.3m placing only a few weeks before.
So whilst i appreciate there will be invoices unpaid etc SKIN has burnt over £500k of cash in Q4 alone.
Based on this IMHO cash will continue to be tight in 2020 and i would not rule out another placing. Look at Open Orphan - 2 placings this year and they are flying as they are using the money appropriately. A placing is not always a negative.
I am happy for you to prove me wrong, but it is clear that the last placing did damage the share price and also damaged SKINs reputation in the short term as the previous 3 or 4 months you had repeatedly told shareholders that cash was fine.